(0.07%) 5 473.23 points
(0.12%) 39 159 points
(0.38%) 17 785 points
(0.07%) $80.89
(-3.66%) $2.66
(-0.79%) $2 312.50
(0.18%) $28.92
(3.67%) $1 022.60
(0.28%) $0.936
(0.70%) $10.68
(0.43%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'...
Stats | |
---|---|
今日成交量 | 2.06M |
平均成交量 | 341 846 |
市值 | 23 816.00 |
EPS | $-0.0348 ( Q1 | 2023-05-15 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.000392 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00100 (1 000.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-18 | Chappell Dale | Sell | 276 210 | Common Stock, $0.001 par value |
2023-10-18 | Chappell Dale | Sell | 75 887 | Common Stock, $0.001 par value |
2023-10-18 | Chappell Dale | Sell | 34 253 | Common Stock, $0.001 par value |
2022-07-27 | Buxton Cheryl | Buy | 78 362 | Stock Option (Right to Buy) |
2022-07-27 | Hohneker John | Buy | 63 195 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
6.21 |
Last 98 transactions |
Buy: 5 830 886 | Sell: 2 957 610 |
音量 相关性
Humanigen, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Humanigen, Inc. 相关性 - 货币/商品
Humanigen, Inc. 财务报表
Annual | 2022 |
营收: | $2.51M |
毛利润: | $2.51M (100.00 %) |
EPS: | $-1.180 |
FY | 2022 |
营收: | $2.51M |
毛利润: | $2.51M (100.00 %) |
EPS: | $-1.180 |
FY | 2021 |
营收: | $3.60M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.98 |
FY | 2020 |
营收: | $312 000 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.42 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Humanigen, Inc.
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。